Plain-English translation of NCT05950464 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination of two experimental medications— (M1774) and ZEN003694—to treat ovarian and endometrial cancer that has returned after previous treatment. The study is designed to find the right dose of these medications when taken together, and to understand how well they work in patients whose cancer cells have specific genetic changes. Researchers believe this combination may be particularly effective for cancers with a mutation in a gene called ARID1A.
Many patients with ovarian and endometrial cancer eventually develop cancer that comes back or stops responding to standard chemotherapy. This medication combination targets a different pathway in cancer cells, offering hope for people who have limited options after their cancer recurs.
You likely qualify if…
You likely don't qualify if…
You will take both medications by mouth daily in 28-day cycles. Throughout the study, you will have regular clinic visits, blood tests, and imaging scans (CT, MRI, or X-ray) to monitor how you are responding and check for side effects. Depending on which part of the trial you join, you may also have tumor biopsies taken before and during treatment to help researchers understand how the medications are working at the cellular level.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States